FDA Review Finds No Increased Risk of Prostate Cancer With Parkinson’s Disease Treatments Containing Entacapone

Aug 15, 2019 – A U.S. Food and Drug Administration (FDA) review of additional data found no increased risk of prostate cancer with the use of entacapone to treat Parkinson’s disease. The FDA conducted this review after an earlier trial – the Stalevo Reduction in Dyskinesia Evaluation–Parkinson’s Disease (STRIDE-PD) trial – suggested this possible risk. As a result, the FDA’s recommendations for using entacapone and the combination of entacapone, carbidopa … (leggi tutto)